Zobrazeno 1 - 10
of 256
pro vyhledávání: '"Osterwalder, B."'
Autor:
Cassidy, J. *, Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., McKendrick, J., Maroun, J., Marshall, J., Osterwalder, B., Pérez-Manga, G., Rosso, R., Rougier, P., Schilsky, R.L.
Publikováno v:
In Annals of Oncology April 2002 13(4):566-575
Autor:
O’Shaughnessy, J.A. *, Blum, J., Moiseyenko, V., Jones, S.E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H.-U., Laws, S.
Publikováno v:
In Annals of Oncology September 2001 12(9):1247-1254
Autor:
Twelves, C *, Boyer, M, Findlay, M, Cassidy, J, Weitzel, C, Barker, C, Osterwalder, B, Jamieson, C, Hieke, K
Publikováno v:
In European Journal of Cancer March 2001 37(5):597-604
Publikováno v:
British Journal of Cancer. 12/15/2009, Vol. 101 Issue 12, p1961-1971. 11p. 4 Charts, 3 Graphs.
Autor:
Osterwalder B, Maurizio Marangolo, Lidia Ukarma, Matti Aapro, Michael Untch, Agustí Barnadas, Robert C. F. Leonard, Armin Scherhag, Hans-Ulrich Burger
Publikováno v:
European Journal of Cancer. 45:2984-2991
Purpose, patients and methods This retrospective analysis of the BRAVE study evaluated the impact of baseline risk factors and antithrombotic therapy on the risk of thrombovascular events (TVEs) in patients receiving epoetin compared to patients not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17b6b67ac9d18abfc897a2d7c7ba688c
https://doi.org/10.1016/j.ejca.2009.06.031
https://doi.org/10.1016/j.ejca.2009.06.031
Publikováno v:
British Journal of Cancer
Background: Epoetin-β is used to treat patients with cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce the risk of blood transfusions and improve quality of life (QoL). Methods: This meta-analysis of all 12 randomised, cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2dbeda59a88a41a461b241859f12c9f
https://doi.org/10.1038/sj.bjc.6605255
https://doi.org/10.1038/sj.bjc.6605255
Publikováno v:
Clinical Chemistry. 55:1354-1360
Background: Hepcidin is thought to be the central regulator of iron metabolism. Iron deficiency is associated with low hepcidin concentrations, and anemia in patients with cancer is associated with high concentrations of hepcidin. Study objectives: O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd7df3bdeed1527f4229771bdc37d2cf
https://doi.org/10.1373/clinchem.2008.121285
https://doi.org/10.1373/clinchem.2008.121285
Autor:
J. L. Misset, Véronique Diéras, Stan B. Kaye, Osterwalder B, Robert C. F. Leonard, Martine Piccart, Manfred Kaufmann, Michel Marty, Gunter von Minckwitz, John Crown
Publikováno v:
The Lancet Oncology. 3:719-727
Summary The anthracyclines doxorubicin and epirubicin, and the taxanes paclitaxel and docetaxel, are effective chemotherapeutic agents for the first-line and second-line treatment of metastatic breast cancer, and their clinical use is widespread. How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f340daa055de008b16e338437223f7
https://doi.org/10.1016/s1470-2045(02)00927-0
https://doi.org/10.1016/s1470-2045(02)00927-0
Autor:
Joyce A. O'Shaughnessy, Vladimir Moiseyenko, Louis Mauriac, Osterwalder B, David Miles, Joanne L. Blum, H. U. Burger, S. Laws, Stephen E. Jones, R. Rosso, D. Bell
Publikováno v:
Annals of Oncology. 12:1247-1254
Background Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer. Patients and methods Ninety-five patients were randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0560b26c82dce0acf91cbf7cf859842
https://doi.org/10.1023/a:1012281104865
https://doi.org/10.1023/a:1012281104865
Autor:
Osterwalder B, K Hieke, Michael Boyer, C Jamieson, C Barker, Chris Twelves, C Weitzel, Jim Cassidy, Michael Findlay
Publikováno v:
European Journal of Cancer. 37:597-604
Standard therapy for advanced or metastatic colorectal cancer consists of 5-fluorouracil plus leucovorin (5-FU/LV) administered intravenously (i.v.). Capecitabine (Xeloda), an oral fluoropyrimidine carbamate which is preferentially activated by thymi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a26d437557435ce1a03ea08ae9afa21f
https://doi.org/10.1016/s0959-8049(00)00444-5
https://doi.org/10.1016/s0959-8049(00)00444-5